Showing posts with label Prostate cancer Market size. Show all posts
Showing posts with label Prostate cancer Market size. Show all posts

Monday, 2 September 2019

Global Prostate Cancer Market: What it got next? Find out with the latest research available at 'The Market Reports'

Overivew
The Global Prostate Cancer Market is expected to grow with a CAGR of approximately 10.5% during the forecast period from 2017-2027. prostate cancer is a disease of the prostate gland. These glands are responsible for the production and secretion of prostate fluid as a component of semen in addition to that it also acts as a regulator of urine control in men.
International Prostate Cancer Market Business Overview:
As per a survey conducted by the American Cancer Society, about 1 in 7 men are estimated to be diagnosed with prostate cancer during their lifetime. Moreover, according to a UK based government institute namely Cancer Research Organization estimated that nearly 46,690 new cases of prostate cancer were diagnosed in 2014 with a death toll of 11,287 patients. Furthermore, there are various initiatives undertaken by key players to collaborate with government organization to spread awareness regarding the clinical symptoms of prostate cancer. Moreover, the promotion of diagnostic & screening tests for early detection such as Digital Rectal Exam (DRE), and Prostate-Specific Antigen (PSA). In addition, major players including Dendreon Corporation, Sanofi, AstraZeneca Plc, Johnson & Johnson Inc., and Astellas Pharms, Inc., are aiming to develop safe and effective therapeutic products to treat tumor.
Besides, blockbuster drugs such as Zytiga, Taxotere, Xtandi, Eligard, Xofigo, and Provenge, holding a robust position in the global prostate cancer market. Johnson & Johnson’s brand Zytiga is considered as a gold standard for the treatment of prostate cancer. Rise in the funding in both private and public sector for the drug development, technological advancements in finding new techniques to fight prostate cancer,  lifestyle changes, are few factors driving the growth of the market. Side effects of surgery such as urinary impotence & incontinence and surgical risks such as blood clots, stroke, and heart attack are certain constraints encountered by the global prostate cancer market.
Prostate Cancer Market Top Key Players Overview:
OncoGenex Pharmaceuticals Inc., Bayer Pharma AG (Germany), Progenics Pharmaceuticals, Inc. (US), TOLMAR Inc. (US), OncBioMune Pharmaceuticals Inc. (US), Endo Pharmaceuticals Inc. (US), Tokai Pharmaceuticals Inc. (US),  Active Biotech (US), ADC Therapeutics (US), Advantagene (US), Advaxis Pharmaceuticals (US), ANI Pharmaceuticals (US), ArQule (US), Athenex Pharmaceuticals (US), Bavarian Nordic (US), BHR Pharma (US), Boehringer Ingelheim (Germany), Cleveland BioLabs (US), Dextech Medical (US), Eisai (US), Endo Pharmaceuticals (US), Ferring Pharmaceutical (US), GTx (US), Innocrin Pharmaceutical (US), Inspyr Therapeutics (US), Io Therapeutics (US), Lidds AB (US), Merck Group (US), Myovant Sciences (US), Northwest Biotherapeutics (US), Novartis AG (Switerzland), Nymox Pharmaceuticals (US), OncoGenex (US), Oncolytics Biotech (US), Orion (US), CureVac (US), Pharmamar (US), Camurus (US), Foresee Pharmaceuticals (US), Progenics Pharmaceuticals (US), Sotio (US), Spectrum Pharmaceuticals (US), Synta (US), Takeda Pharmaceuticals (Japan), Teva Pharmaceutical (Israel), Tokai Pharmaceuticals (US), AbbVie (US),  Astellas Pharma (Japan), AstraZeneca (US), Johnson & Johnson (US), Sanofi (France), Ipsen (US), Valeant Pharmaceuticals (US), Dendreon Corporation (US), and others are some of the prominent players at the forefront of competition in the global prostate cancer market and are profiled in MRFR Analysis.
Industry Updates
March, 2018 Astellas pharma received FDA approval for Xtandi tablets, a treatment for castration-resistant prostate cancer, in Japan
Jan, 2015 Janssen Pharmaceutical Companies r received FDA approval for Zytiga (abiraterone acetate) for the treatment of prostate cancer
Global Prostate Cancer Market - Regional Analysis:
The global prostate cancer market is segmented into five major regions including Americas, Europe, Asia Pacific, and Middle East and Africa region.
Americas dominated the global prostate cancer market in terms of revenue share owing to the increasing R&D in the region and presence of big outsourcing firms. In the U.S., it is the most common cancer in men, but it is also treatable if found in the early stages. Prostate Cancer Foundation of Canada supports research, cure, and prevention of prostate cancer via online portal. According to the American Cancer Society in 2017 expected that about 161,360 new cases of prostate cancer will be diagnoses, and that around 26,730 fatalities will occur because of it.
The European market is the second largest market for prostate cancer plays an important role to minimize the cost of clinical trials. Furthermore, Asia Pacific region has emerged as the fastest growing market for prostate cancer.
The Middle-East and Africa prostate cancer market has been evaluated as moderately growing market and it is expected that the market will continue to grow at same pace in the near future.
Table of Contents
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels: , , , ,

Thursday, 30 May 2019

Prostate cancer Market Rising Healthcare Expenditure In Emerging Regions And Developed Economies!!

Prostate Cancer Market study with Detailed Review, Portraying about the Product/Industry Scope and Expounds Industry Outlook and status to 2027.

Global Prostate cancer Market – Overview
The global prostate cancer market is showing the steady growth; mainly owing to increase in patient population. According to report published by Centers for Disease Control and Prevention, in 2014, there were around 172,258 men in the United States, who diagnosed with prostate cancer and around 28,343 men died from prostate cancer. These rising number of prostate cancer create an opportunity for the player to introduce innovative treatment option.


Companies are continuously invent new treatment to capture the global market. Thus players invest more in research and development activities. In this regards, Bayer Pharma AG announced that they have many drugs for the treatment of prostate cancer in there pipeline such as Radium-223 dichloride and BAY 1841788 (ODM-201, AR antagonist).
Progenics Pharmaceuticals, Inc., 2015, acquired Exini Diagnostics AB in order to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to help patients and physicians understand, target and treat prostate cancer. These companies are more investing in research and development program to provide the best treatment option, which help them to keep ahead with their competitor.
These acquisitions help companies to provide better treatment opportunity in the market and hence improve the quality of life for the people around the world. Additionally it help market players in translating breakthrough science into innovative treatment to help people with prostate cancer worldwide.

Competitive Analysis
Some of the noteworthy players in the global prostate cancer market include Progenics Pharmaceuticals, Inc. (US), Endo Pharmaceuticals Inc. (Ireland), Bayer Pharma AG (Berlin), OncoGenex Pharmaceuticals Inc. (US), OncBioMune Pharmaceuticals Inc. (US), TOLMAR Inc. (US), and others.
January 30th, 2019, Researchers at the Medical University of South Carolina revealed the successful completion of the world’s first-ever prostate cancer surgery by using Blu Build Cesium-131 brachytherapy delivery system.
February 15th, 2019, Bayer partnering with Orion revealed the numbers showcasing the efficacy of their drug, darolutamide. The report revealed that the drug helped curb down the risk of metastasis or even death by a striking 59% in patients with non-metastatic castration-resistant prostate cancer.
Prostate Cancer Market - Segmentation
The global prostate cancer market segmentation is done on the basis of end-users and product type.
By product type, the market includes hormone therapy, targeted therapies, therapeutic vaccines, and others.
By end-users, the market segments into clinics, hospitals, and others.


Regional Analysis
The regional segmentation of the global prostate cancer market is spearheaded by North America and includes other notable regions like Europe, Asia-Pacific, and Middle East & Africa.
North Americas’ dominant standing in the market is expected to grow further during the forecast period. This can be credited primarily due to the high obesity population. This has prompted the government to be more focused on research and development activities, thereby bringing forward the best treatment facilities for the affected population.
Europe is another huge market for prostate cancer because of the huge existing population affected by this condition. Well-developed treatment facilities, the presence of major market players, and the government’s repeated effort in spreading awareness and educating the population about prostate cancer are all important drivers of the market. 
Asia-Pacific is another region expected to grow during the review period due to the presence of a huge population being affected with the condition. Highly populated countries in this region, India and China, have a huge obesity population, which can potentially lead to incidences of prostate cancer.
Plus, these countries are willing to adopt new technologies and treatment options from developed countries. This is pushing the market growth herein. The Middle East and Africa region boast the least growth potential among all the mentioned regions.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for Asia Pacific, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Posted by at No comments:
Labels: , , , ,
Subscribe to: Posts (Atom)